Bionik Laboratories Corp.
483 Bay Street
Office N105
Toronto
Ontario
M5G 2C9
Canada
Tel: 416-640-7887
Website: http://www.bioniklabs.com/
About Bionik Laboratories Corp.
Bionik Laboratories is a global, pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders. Through the acquisition of Interactive Motion Technologies, Bionik has added a portfolio of products focused on upper and lower extremity rehabilitation of stroke patients. The Company now has three products available on the market and three products in varying stages of development.YEAR FOUNDED:
2010
LEADERSHIP:
Founder and COO: Michal Prywata
CEO: Peter Bloch
CSO: Hermano Krebs
CFO: Leslie N. Markow
CCO: Timothy A. McCarthy
JOBS:
Please click here for Bionik Labs job opportunities.
PRODUCTS:
All Products
FOLLOW BIONIK LABS:
Tweets by Bionik Labs
58 articles about Bionik Laboratories Corp.
-
Bionik Laboratories Expands Its Partnership With Lifepoint Health With the Installation of InMotion® Robotic Devices at Four New Locations
6/15/2023
Bionik Laboratories Corp., continues to grow its partnership with Lifepoint Health, announcing its four new installations of the InMotion® ARM robotic device in Phoenix, Arizona, Sacramento, California, Brownsburg, Indiana, and Louisville, Kentucky, to deliver quality stroke recovery care.
-
Bionik Laboratories’ InMotion® Robotic Devices on Display at the Korea International Medical & Hospital Equipment Show (KIMES)
3/23/2023
Bionik Laboratories Corp. today announced its InMotion® Robots will be on display at the Korea International Medical & Hospital Equipment Show (KIMES) from March 23 – March 26, 2023.
-
Bionik Laboratories to Present at the Q4 Virtual Investor Summit
11/7/2022
Bionik Laboratories Corp. will present at the 2022 Investor Summit Q4 Micro-Cap Conference.
-
Bionik Laboratories Appoints Richard Russo, Jr. as Chief Executive Officer and Dan Gonsalves as Chief Financial Officer
10/13/2022
Bionik Laboratories Corp . today announced the appointments of Richard Russo, Jr. as Chief Executive Officer and President, who previously served as Chief Financial Officer.
-
BIONIK Laboratories to Present at National Investment Banking Association Conference
9/1/2022
BIONIK Laboratories Corp. announced that Richard Russo, Interim CEO, will present a corporate overview at the National Investment Banking Association conference on September 8, 2022.
-
BIONIK Laboratories Corp. to Present at Investor Summit Group’s Q3 Virtual Conference
8/9/2022
BIONIK Laboratories Corp. today announced that Rich Russo, Chief Financial Officer and Interim Chief Executive Officer, will be presenting a corporate overview and meeting with institutional investors at the Q3 Virtual Investor Summit.
-
BIONIK Laboratories Announces the Sale & Installation of a New InMotion® ARM/HAND Robotic Device to Tampa General Hospital for its Rehabilitation Center
6/23/2022
BIONIK Laboratories Announces the Sale & Installation of a New InMotion ® ARM/HAND Robotic Device to Tampa General Hospital for its Rehabilitation Center.
-
BIONIK Laboratories Reports Fourth Quarter and Fiscal Year 2022 Financial Results
6/9/2022
BIONIK Laboratories Corp. (OTCPink: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for the fourth quarter and fiscal year 2022, ended March 31, 2022.
-
BIONIK Laboratories Reports 15-20% Increase in Therapeutic Gains on InMotion® Robotic Devices in New Patient Outcomes Data Report
3/29/2022
BIONIK Laboratories Reports 15-20% Increase in Therapeutic Gains on InMotion ® Robotic Devices in New Patient Outcomes Data Report.
-
BIONIK Laboratories Reports Third Quarter Fiscal Year 2022 Financial Results
2/9/2022
BIONIK Laboratories Corp. today reported financial results for the third quarter and first nine months of fiscal year 2022, ended December 31, 2021.
-
BIONIK Laboratories InMotion® Robotics Technology Meets the Recovery Demands from an Increase of Stroke Patients Brought on by Severe Cases of COVID-19
12/17/2021
BIONIK Laboratories Corp today announced its unique position to meet the increased recovery demands from stroke patients who have suffered from a severe case of COVID-19.
-
BIONIK Laboratories to Participate at MEDICA, a Leading International Trade Show for the Medical Industry
11/11/2021
BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced its participation in the MEDICA Trade Show in Dusseldorf, Germany from November 15–18, 2021.
-
BIONIK Laboratories Announces Commercial Team Addition With Newly Hired Regional Sales Director, Tony Bellofatto
10/28/2021
BIONIK Laboratories Corp. today announced the hiring of a new Regional Sales Director, Tony Bellofatto.
-
BIONIK Laboratories Reports a 72% Increase in Patient Sessions on its InMotion® Robotic Devices Since Launch of InMotion Connect™ Platform
9/22/2021
BIONIK Laboratories Corp . today announced hospitals and other healthcare facilities utilizing InMotion Connect™ have seen a 72% increase in patient sessions on InMotion® robotic devices nationwide since the launch of the proprietary data platform last year.
-
BIONIK Laboratories Reports Fiscal 2022 Q1 Financial Results
8/12/2021
BIONIK Laboratories Corp . today reported financial results for its first quarter of fiscal year 2022, for the period ended June 30, 2021.
-
BIONIK Laboratories Announces Resignation of CEO, Names Interim CEO
7/19/2021
BIONIK Laboratories Corp. today has announced that Chief Executive Officer and Board Member Dr. Eric Dusseux has resigned as Chief Executive Officer and stepped down from the board
-
BIONIK Laboratories Announces Fiscal 2021 Q2 Financial Results
11/12/2020
BIONIK Laboratories Corp . (OTCQB: BNKL) , a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for its second quarter of fiscal year 2021, ending September 30, 2020. Financial highlights for the second quarter of fiscal 2021 and recent weeks include:
-
BIONIK Laboratories Announces Sale of New InMotion® ARM/HAND Robotic Device to VA Rehabilitation Research & Development’s Center for Neurorestoration and Neurotechnology
9/30/2020
BIONIK Laboratories Announces Sale of New InMotion ® ARM/HAND Robotic Device to VA Rehabilitation Research & Development’s Center for Neurorestoration and Neurotechnology VA-funded center purchases second InMotion ® ARM/HAND interactive therapy system to test new approaches for restoring physical function of veterans with neurologic disease or injury TORONTO & BOSTON--( BUSINESS WIRE )-- BIONIK Laboratories Corp . (OTCQB:BNKL) ("BIONIK" or
-
BIONIK Laboratories Announces Fiscal 2020 Financial Results
6/30/2020
BIONIK Laboratories Corp . (OTCQB:BNKL) ("BIONIK"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the fiscal year ended March 31, 2020. Financial highlights for the fiscal year 2020 and recent weeks include : Reported sales of $2,153,354 for
-
BIONIK Laboratories Donates InMotion® Robotic System to Einstein Healthcare Network’s MossRehab for Use in New COVID-19 Rehab Unit
5/12/2020
MossRehab, led by renowned Dr. Alberto Esquenazi, utilizing BIONIK’s robotic therapy system in new CORE+ Unit to treat patients infected with or recovering from COVID-19 TORONTO & BOSTON--( BUSINESS WIRE )-- BIONIK Laboratories Corp . (OTCQB:BNKL) ("BIONIK"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced it h